Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Follow-up After 177Lu-IPN01072
2024-515071-35-00Phase 4Completed
- Sponsor
- Ariceum Therapeutics
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of satoreotide in apudoma (NET), sponsored by Ariceum Therapeutics. Started Oct 2024; status: completed.
02
Drugs
satoreotide
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2024-515071-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515071-35-00.